esanum talks with Prof. Brunetti about AI in medicine, its ethical implications and physicians' approach to this tech revolution.
Trial results show equal DA-EPOCH-R efficacy to CODOX-M/R-IVAX as first-line treatment in patients, but less toxicity.
New technologies have transformed haematology. Gene-editing and molecular agents become available to patients within shorter timeframes.
A Chinese meta-analysis of studies on the treatment of scleroderma has investigated whether ACE inhibitors can be used to prevent renal crisis.
esanum talks with Prof. Bonini about her research projects, her EHA board role and the prospects for young hematologists who wish to engage in research.
Leniolisib is safe, increases naïve B cells, decreases lymphadenopathy and spleen size, and improves cytopenia in APDS/PASLI.
Early ASCT in lenalidomide / bortezomib / dexamethasone therapy followed by lenalidomide maintenance, significantly improves PFS for newly diagnosed MM
Exa-cel gene-editing therapy is associated with increase in foetal and total Hb in transfusion-dependent β-thalassemia or severe sickle cell disease patients.
Phase-3 trial shows improved PFS with venetoclax/obinutuzumab/ibrutinib therapy in fit, untreated patients with chronic lymphocytic leukaemia.
A new platform connects the spheres of medical care and health innovation. It allows caregivers to find assignments with innovation actors, including companies.
CPX-351 does not improve response, overall survival, or event-free survival compared with FLAG-Ida in AML patients with adverse cytogenetics.
Continued treatment with luspatercept, for up to 3 years, allowed more patients to experience a reduction in red blood cell transfusion burden.
Large-scale whole-genome sequencing, whole-exome sequencing, and RNA-expression profiling found new T-cell acute lymphoblastic leukaemia subtypes.
OS improves when combined with standard induction and consolidation therapy, and as continuation therapy as a single agent for up to 3 years in patients.
A subgroups analysis of patients aged 65 years or older in ZUMA-7 demonstrated axi-cel to be superior to standard-of-care for second-line treatment.
Post-trial data support caplacizumab's long-term safety and efficacy in acquired or immune-mediated thrombotic thrombocytopenic purpura patients.
Nivolumab and radiotherapy at a single lesion is well tolerated and leads to an abscopal response in most of relapsed/refractory HL cases.
The phase 3 MOMENTUM trial show a significant improvement in symptoms, spleen size, and anaemia measures with momelotinib over danazol.
Phase-3 ATLAS trial shows the post-transplant maintenance therapy benefit of carfilzomib, lenalidomide, and dexamethasone over lenalidomide.
AML has high patient-to-patient treatment response variability. Pharmacoscopy allows ex vivo drug-response profiling of tumour cells, enabling tailored treatments.